 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 October 2002 | Volume 137 Issue 8 | Pages 648-655
Background: Warfarin is used for prophylaxis of venous thromboembolism in patients undergoing total knee arthroplasty. However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38% to 55% and requires routine coagulation monitoring and frequent dose adjustment. Ximelagatran, an oral direct thrombin inhibitor, has shown promising efficacy and tolerability in patients undergoing total hip or knee arthroplasty.
Objective: To compare the efficacy and safety of ximelagatran and warfarin for prophylaxis of venous thromboembolism after total knee arthroplasty.
Design: Randomized, double-blind, parallel-group trial.
Setting: 74 North American hospitals.
Patients: 680 patients who had undergone total knee arthroplasty.
Intervention: 7 to 12 days of treatment with oral ximelagatran, 24 mg twice daily, starting on the morning after surgery, or warfarin (target international normalized ratio, 2.5 [range, 1.8 to 3.0]), starting on the evening of the day of surgery.
Measurements: Principal end points were asymptomatic DVT on mandatory venography; symptomatic DVT confirmed by ultrasonography or venography; symptomatic, objectively proven pulmonary embolism; and bleeding. All were assessed by blinded adjudication locally and at a central study laboratory.
Results: On central adjudication, incidence of venous thromboembolism was 19.2% (53 of 276 patients) in the ximelagatran group and 25.7% (67 of 261 patients) in the warfarin group (difference, –6.5 percentage points [95% CI, –13.5 to 0.6 percentage points]; P = 0.070). On local assessment, incidence was 25.4% in the ximelagatran group and 33.5% in the warfarin group (P = 0.043). In the ximelagatran and warfarin groups, respectively, major bleeding occurred in 1.7% and 0.9% of patients and minor bleeding occurred in 7.8% and 6.4% of patients. No variables related to bleeding differed significantly between the two groups.
Conclusions: For prophylaxis of venous thromboembolism, fixed-dose ximelagatran started the morning after total knee arthroplasty is well tolerated and at least as effective as warfarin, but it does not require coagulation monitoring or dose adjustment.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From University of Rochester School of Medicine and Dentistry, Rochester, New York; University of Washington School of Medicine and Swedish Medical Center, Seattle, Washington; AstraZeneca, Wilmington, Delaware; University of Pennsylvania, Philadelphia, Pennsylvania; McMaster University, Hamilton, Ontario, Canada; University of California, Los Angeles, Los Angeles, California; and Scripps Clinic and Research Foundation, La Jolla, California.
Potential Financial Conflicts of Interest:Employment: S.D. Berkowitz, A.K. Webster, J.P. Whipple, G.R. Peters; Consultancies: C.W. Francis, B.L. Davidson, S.D. Berkowitz, P.A. Lotke, J.S. Ginsberg, J.R. Lieberman; Honoraria: C.W. Francis, B.L. Davidson, S.D. Berkowitz, J.R. Lieberman; Stock ownership: S.D. Berkowitz, A.K. Webster; Grants received: J.S. Ginsberg, C.W. Colwell Jr.
Requests for Single Reprints: Charles W. Francis, MD, Hematology/Oncology Unit, Department of Medicine, University of Rochester Medical Center, Box 610, 601 Elmwood Avenue, Rochester, NY 14642; e-mail, charles_francis{at}urmc.rochester.edu.
Current Author Addresses: Dr. Francis: Hematology/Oncology Unit, Department of Medicine, University of Rochester Medical Center, Box 610, 601 Elmwood Avenue, Rochester, NY 14642.
Dr. Davidson: University of Washington School of Medicine and Swedish Medical Center, 801 Broadway, Suite 915, Seattle, WA 98122.
Dr. Berkowitz, Ms. Webster, Mr. Whipple, and Dr. Peters: DCC2, 1800 Concord Pike, Wilmington, DE 19850.
Dr. Lotke: University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104.
Dr. Ginsberg: McMaster University Medical Centre, Room 3X28, 1200 Main Street West, Hamilton, Ontario L87 3Z5, Canada.
Dr. Lieberman: UCLA Medical Center, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095.
Dr. Colwell: Scripps Clinic, 10666 North Torrey Pines, La Jolla, CA 92037.
Author Contributions: Conception and design: C.W. Francis, B.L. Davidson, P.A. Lotke, J.S. Ginsberg, J.P. Whipple, G.R. Peters, C.W. Colwell Jr.
Analysis and interpretation of the data: C.W. Francis, B.L. Davidson, S.D. Berkowitz, P.A. Lotke, J.S. Ginsberg, J.R. Lieberman, J.P. Whipple, G.R. Peters, C.W. Colwell Jr.
Drafting of the article: C.W. Francis, B.L. Davidson, S.D. Berkowitz, P.A. Lotke, J.S. Ginsberg, G.R. Peters.
Critical revision of the article for important intellectual content: C.W. Francis, B.L. Davidson, S.D. Berkowitz, P.A. Lotke, J.R. Lieberman, G.R. Peters, C.W. Colwell Jr.
Final approval of the article: C.W. Francis, B.L. Davidson, P.A. Lotke, J.S. Ginsberg, J.R. Lieberman, G.R. Peters, C.W. Colwell Jr.
Provision of study materials or patients: B.L. Davidson, P.A. Lotke.
Statistical expertise: B.L. Davidson, J.P. Whipple.
Obtaining of funding: G.R. Peters.
Administrative, technical, or logistic support: B.L. Davidson, A.K. Webster, G.R. Peters.
Collection and assembly of data: B.L. Davidson, S.D. Berkowitz, G.R. Peters. ARTICLE
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
A Randomized, Double-Blind Trial
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. B. Haas, R. L. Barrack, G. Westrich, and P. F. Lachiewicz Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty J. Bone Joint Surg. Am., December 1, 2008; 90(12): 2764 - 2780. [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P S Sidhu, R Alikhan, T Ammar, and D J Quinlan Lower limb contrast venography: a modified technique for use in thromboprophylaxis clinical trials for the accurate evaluation of deep vein thrombosis Br. J. Radiol., November 1, 2007; 80(959): 859 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Stone, B. H. Tonnessen, and S. R. Money The New Anticoagulants Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2007; 19(3): 332 - 335. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Motte, C. M. Samama, J. Guay, J. Barre, J.-Y. Borg, and N. Rosencher Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis: [La prevention de la thromboembolie veineuse postoperatoire. Evaluation du risque et methodes de prophylaxie] Can J Anesth, June 1, 2006; 53(6_suppl): S68 - S79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Colwell Jr., S. D. Berkowitz, J. R. Lieberman, P. C. Comp, J. S. Ginsberg, G. Paiement, J. McElhattan, A. W. Roth, C. W. Francis, and The EXULT B Study Group Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty J. Bone Joint Surg. Am., October 1, 2005; 87(10): 2169 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Lieberman and W. K. Hsu Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2097 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gulseth Ximelagatran: An orally active direct thrombin inhibitor Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1451 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Katira, A Chauhan, and R S More Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation Postgrad. Med. J., June 1, 2005; 81(956): 370 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gurewich Ximelagatran--Promises and Concerns JAMA, February 9, 2005; 293(6): 736 - 739. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, M. O'Donnell, and J. I. Weitz New anticoagulants Blood, January 15, 2005; 105(2): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Halperin Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation J. Am. Coll. Cardiol., January 4, 2005; 45(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E Dager, T. G Vondracek, B. A McIntosh, and E. A Nutescu Ximelagatran: An Oral Direct Thrombin Inhibitor Ann. Pharmacother., November 1, 2004; 38(11): 1881 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 338S - 400S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bombeli and D. R. Spahn Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage Br. J. Anaesth., August 1, 2004; 93(2): 275 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Wallentin Oral direct thrombin inhibition for anticoagulation in coronary artery disease - focus on the ESTEEM trial Eur. Heart J. Suppl., April 1, 2004; 6(suppl_B): B9 - B14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Auerbach and J. Kleinbart Update in Hospital Medicine Ann Intern Med, March 2, 2004; 140(5): 363 - 369. [Full Text] [PDF]
|
|
|
|
|
|
E. A Nutescu and A. K Wittkowsky Direct Thrombin Inhibitors for Anticoagulation Ann. Pharmacother., January 1, 2004; 38(1): 99 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Goldhaber and C. G. Elliott Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention Circulation, December 9, 2003; 108(23): 2834 - 2838. [Full Text] [PDF]
|
|
|
|
|
|
G. E. Raskob and J. Hirsh Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery Chest, December 1, 2003; 124(6_suppl): 379S - 385S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Francis, S. D. Berkowitz, P. C. Comp, J. R. Lieberman, J. S. Ginsberg, G. Paiement, G. R. Peters, A. W. Roth, J. McElhattan, C. W. Colwell Jr., et al. Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement N. Engl. J. Med., October 30, 2003; 349(18): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulman, K. Wahlander, T. Lundstrom, S. B. Clason, H. Eriksson, and the THRIVE III Investigators Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran N. Engl. J. Med., October 30, 2003; 349(18): 1713 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer A 60-Year-Old Woman With Atrial Fibrillation JAMA, October 22, 2003; 290(16): 2182 - 2189. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Heit The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism Chest, September 1, 2003; 124(3_suppl): 40S - 48S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Hyers Management of Venous Thromboembolism: Past, Present, and Future Arch Intern Med, April 14, 2003; 163(7): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Alving, C. W. Francis, W. R. Hiatt, and M. R. Jackson Consultations on Patients with Venous or Arterial Diseases Hematology, January 1, 2003; 2003(1): 540 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 New Drug for VTE Prevention Journal Watch (General), November 15, 2002; 2002(1115): 5 - 5. [Full Text]
|
|
Article
